Achieve Life Sciences (ACHV) Non-Current Assets (2010 - 2026)
Achieve Life Sciences (ACHV) posted Non-Current Assets of $2.0 million for Q1 2026, up 7.52% on a QoQ basis from $1.9 million in Q4 2025, and down 13.32% year-over-year from $2.4 million in Q1 2025.
Achieve Life Sciences (ACHV) Non-Current Assets (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- Quarterly Non-Current Assets fell 13.32% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (down 13.31% YoY) and the FY2025 annual result came in at $1.9 million, down 12.23% from the prior year.
- Non-Current Assets was $2.0 million for Q1 2026 at Achieve Life Sciences, up from $1.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.9 million in Q1 2022 and bottomed at $1.9 million in Q4 2025.
- A 5-year average of $2.4 million and a median of $2.4 million in 2024 frame the typical range for Non-Current Assets.
- Peak annual rise in Non-Current Assets reached 1.64% in 2025, while the deepest fall reached 16.88% in 2025.
- Achieve Life Sciences' Non-Current Assets stood at $2.6 million in 2022, then fell by 9.54% to $2.4 million in 2023, then retreated by 9.33% to $2.2 million in 2024, then fell by 12.23% to $1.9 million in 2025, then climbed by 7.52% to $2.0 million in 2026.
- Business Quant data shows ACHV's Non-Current Assets at $2.0 million in Q1 2026, $1.9 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Achieve Life Sciences | 2.54 Mn | 2.54 Mn | - | 2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.27 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 2.39 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.54 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.64 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | 2.84 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 3.07 Mn |
| Jun 30, 2021 | 3.13 Mn |